Positron Announces Sales of Attrius(TM) PET Scanners; Reaffirms Growth Targets

/ Source: GlobeNewswire

INDIANAPOLIS, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, announced today it has placed orders on its sales of three Attrius™ PET scanners. The sales of these systems are for leading cardiology practices and hospitals. The Company also reaffirmed its growth targets as previously disclosed, and is anticipating steady growth acceleration through 2012.

"The outlook for 2010 and beyond is very promising - with our leading market position and steady increase of new orders, the next few years should be an exciting period for Positron.  Cardiac PET is the future of nuclear cardiology and we believe the investments made in equipment and infrastructure should allow us to meet the growing interest in PET. Our overriding objective is to meet the strong demand and be the provider of choice for cardiac PET adopters," said Patrick G. Rooney, chief executive officer of Positron. "While we're extremely focused on excelling in this rapidly growing field, we're also very focused on expanding our pharmaceutical business. This enables us to combine our unique products in innovative ways that provides the full package to the cardiology industry. All of our actions have one common goal in mind of increasing the bottom line that will deliver value to our shareholders."

Positron has received additional orders during the third quarter of 2010 and anticipates the fourth quarter will be its strongest yet. With the current run rate, the Company fully anticipates by the end of 2010 it will reach its sales goal of approximately 12 to 15 Attrius™ PET systems which equates to approximately $10 million to $12 million in sales, part of which will be recognized in the first quarter of 2011. The Company also expects to begin generating revenue from its radiopharmaceutical distribution and manufacturing businesses, which should come on line at the beginning of the fourth quarter. 

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at .

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

CONTACT: Positron Corporation Patrick G. Rooney (317) 576-0183